You are here: Home > Knowledge bank > News
  • Home or Away – All Due Care still required for the EPO

    1 August 2019

    Anyone involved with patent prosecution will know that deadlines are an everyday fact of life.  Missing a time limit set by the European Patent Office (EPO) can result in a loss of rights, which can be irreversible. This article discusses a decision by the EPO Board of Appeal on a case where a deadline was […]

    Read more >
  • New Munich Office Address

    3 June 2019

    As of 1 June, we have a new office location in Munich, on Kaulbach Strasse, Schwabing, in the heart of Munich.  Uli Wittmann, who joined us as a Partner on 1 April, along with Ute Pfaller and Henriette März, and other colleagues including Trainee Attorneys and Paralegals. The new office will host a total of […]

    Read more >
  • Innovation by Artificial Intelligence and the role of AI in pharmaceutical discovery

    31 May 2019

    Through the ability of Artifical Intelligence, the health care sector can find solutions to effective treatment to cure diseases.   Partner, Adrian Tombling explores why AI is huge for drug research and what impact this could have on the pharmaceutical industry. As AI is created by a computer, it does raise the question, who owns […]

    Read more >
  • Brexit: Impact on IP in Europe

    12 April 2019

    Here’s what we know now The UK began the formal process of leaving the EU on 29 March 2017. The date on which Brexit will have a legal effect on any IP rights will depend on the nature of any withdrawal agreements, transition periods or extensions that are agreed upon. Therefore the ‘date of legal […]

    Read more >
  • Dosage regime relief!

    11 April 2019

    A unanimous decision by the Supreme Court is being hailed as a relief for innovators in the pharmaceutical sector, and confirms that novel and inventive dosage regimes are patentable. Tadalafil (Cialis) is a second in class PDE5 inhibitor for the treatment of erectile dysfunction. This use of tadalafil was first disclosed in EP 0839040 (the […]

    Read more >
  • Pain for Warner-Lambert at the Supreme Court

    13 December 2018

    The eagerly awaited Supreme Court judgment in the Warner-Lambert V Generics (UK) and Actavis case has recently been issued (see here), a full nine months after the hearing in February 2018. This is the final step in a saga which has been ongoing for years, and which is of huge importance to the pharmaceutical industry. […]

    Read more >